305 related articles for article (PubMed ID: 31597607)
21. Lipid mediators of liver injury in nonalcoholic fatty liver disease.
Liangpunsakul S; Chalasani N
Am J Physiol Gastrointest Liver Physiol; 2019 Jan; 316(1):G75-G81. PubMed ID: 30383414
[TBL] [Abstract][Full Text] [Related]
22. Micronutrient Antioxidants and Nonalcoholic Fatty Liver Disease.
Chen G; Ni Y; Nagata N; Xu L; Ota T
Int J Mol Sci; 2016 Aug; 17(9):. PubMed ID: 27563875
[TBL] [Abstract][Full Text] [Related]
23. The Role of Dendritic Cells in Fibrosis Progression in Nonalcoholic Fatty Liver Disease.
Almeda-Valdes P; Aguilar Olivos NE; Barranco-Fragoso B; Uribe M; Méndez-Sánchez N
Biomed Res Int; 2015; 2015():768071. PubMed ID: 26339640
[TBL] [Abstract][Full Text] [Related]
24. Non-Alcoholic Fatty Liver Disease.
Engin A
Adv Exp Med Biol; 2017; 960():443-467. PubMed ID: 28585211
[TBL] [Abstract][Full Text] [Related]
25. Obesity, Nonalcoholic Fatty Liver Disease and Adipocytokines Network in Promotion of Cancer.
Divella R; Mazzocca A; Daniele A; Sabbà C; Paradiso A
Int J Biol Sci; 2019; 15(3):610-616. PubMed ID: 30745847
[TBL] [Abstract][Full Text] [Related]
26. Antioxidant Mechanisms in Nonalcoholic Fatty Liver Disease.
Liu W; Baker SS; Baker RD; Zhu L
Curr Drug Targets; 2015; 16(12):1301-14. PubMed ID: 25915484
[TBL] [Abstract][Full Text] [Related]
27. Chemokine ligand 2 and paraoxonase-1 in non-alcoholic fatty liver disease: The search for alternative causative factors.
Camps J; Joven J
World J Gastroenterol; 2015 Mar; 21(10):2875-82. PubMed ID: 25780284
[TBL] [Abstract][Full Text] [Related]
28. Plumbagin reduces obesity and nonalcoholic fatty liver disease induced by fructose in rats through regulation of lipid metabolism, inflammation and oxidative stress.
Pai SA; Munshi RP; Panchal FH; Gaur IS; Mestry SN; Gursahani MS; Juvekar AR
Biomed Pharmacother; 2019 Mar; 111():686-694. PubMed ID: 30611993
[TBL] [Abstract][Full Text] [Related]
29. Role of lipids in the metabolism and activation of immune cells.
Hubler MJ; Kennedy AJ
J Nutr Biochem; 2016 Aug; 34():1-7. PubMed ID: 27424223
[TBL] [Abstract][Full Text] [Related]
30. Oxidized LDL at the crossroads of immunity in non-alcoholic steatohepatitis.
Houben T; Brandsma E; Walenbergh SMA; Hofker MH; Shiri-Sverdlov R
Biochim Biophys Acta Mol Cell Biol Lipids; 2017 Apr; 1862(4):416-429. PubMed ID: 27472963
[TBL] [Abstract][Full Text] [Related]
31. Insecticide Exposure and Development of Nonalcoholic Fatty Liver Disease.
Yang JS; Park Y
J Agric Food Chem; 2018 Oct; 66(39):10132-10138. PubMed ID: 30193066
[TBL] [Abstract][Full Text] [Related]
32. The role of immune mechanisms in alcoholic and nonalcoholic steatohepatitis: a 2015 update.
Sutti S; Bruzzì S; Albano E
Expert Rev Gastroenterol Hepatol; 2016; 10(2):243-53. PubMed ID: 26634783
[TBL] [Abstract][Full Text] [Related]
33. Modulation of hepatic lipid metabolism by olive oil and its phenols in nonalcoholic fatty liver disease.
Priore P; Cavallo A; Gnoni A; Damiano F; Gnoni GV; Siculella L
IUBMB Life; 2015 Jan; 67(1):9-17. PubMed ID: 25631376
[TBL] [Abstract][Full Text] [Related]
34. An Overview of Lipid Metabolism and Nonalcoholic Fatty Liver Disease.
Pei K; Gui T; Kan D; Feng H; Jin Y; Yang Y; Zhang Q; Du Z; Gai Z; Wu J; Li Y
Biomed Res Int; 2020; 2020():4020249. PubMed ID: 32733940
[TBL] [Abstract][Full Text] [Related]
35. Berberine improves glucogenesis and lipid metabolism in nonalcoholic fatty liver disease.
Zhao L; Cang Z; Sun H; Nie X; Wang N; Lu Y
BMC Endocr Disord; 2017 Feb; 17(1):13. PubMed ID: 28241817
[TBL] [Abstract][Full Text] [Related]
36. The Differential Roles of T Cells in Non-alcoholic Fatty Liver Disease and Obesity.
Van Herck MA; Weyler J; Kwanten WJ; Dirinck EL; De Winter BY; Francque SM; Vonghia L
Front Immunol; 2019; 10():82. PubMed ID: 30787925
[TBL] [Abstract][Full Text] [Related]
37. The intersection of nonalcoholic fatty liver disease and obesity.
Woo Baidal JA; Lavine JE
Sci Transl Med; 2016 Jan; 8(323):323rv1. PubMed ID: 26819197
[TBL] [Abstract][Full Text] [Related]
38. C-Jun/C7ORF41/NF-κB axis mediates hepatic inflammation and lipid accumulation in NAFLD.
Yan FJ; Wang X; Wang SE; Hong HT; Lu J; Ye Q; Zheng YL; Wang YJ
Biochem J; 2020 Feb; 477(3):691-708. PubMed ID: 31957809
[TBL] [Abstract][Full Text] [Related]
39. Arachidonic Acid Metabolites in Cardiovascular and Metabolic Diseases.
Sonnweber T; Pizzini A; Nairz M; Weiss G; Tancevski I
Int J Mol Sci; 2018 Oct; 19(11):. PubMed ID: 30360467
[TBL] [Abstract][Full Text] [Related]
40. Hepatic transcriptome signatures in patients with varying degrees of nonalcoholic fatty liver disease compared with healthy normal-weight individuals.
Suppli MP; Rigbolt KTG; Veidal SS; Heebøll S; Eriksen PL; Demant M; Bagger JI; Nielsen JC; Oró D; Thrane SW; Lund A; Strandberg C; Kønig MJ; Vilsbøll T; Vrang N; Thomsen KL; Grønbæk H; Jelsing J; Hansen HH; Knop FK
Am J Physiol Gastrointest Liver Physiol; 2019 Apr; 316(4):G462-G472. PubMed ID: 30653341
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
